Monoclonal Antibody to COVID 19
Also Known As: Monoclonal Antibody, Xevudy, Bamlanivimab/Etesevimab, Casirivimab/Imdevimab, Tixagevimab/cilgavimab, Regdanvimab
Casirivimab/imdevimab
Casirivimab/imdevimab, sold under the brand name REGEN-COV among others,[74][75] is a combination medicine used for the treatment and prevention of COVID-19.[75] It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection.[76][74][75] The combination of two antibodies is intended to prevent mutational escape.[77] It is also available as a co-formulated product.[76] It was developed by the American biotechnology company Regeneron Pharmaceuticals.[78][79]
Bamlanivimab/etesevimab
Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19.[86][87][88][89] Both types of antibody target the surface spike protein of SARS‑CoV‑2.[90][91]
Bamlanivimab and etesevimab, administered together, are authorized in the United States for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.[92][93] They are also authorized, when administered together, for use after exposure to the SARS-CoV-2 virus for post-exposure prophylaxis (prevention) for COVID-19 and are not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus.[92][93]Sotrovimab
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2.[94][95][96] It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.[95][97] Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.[95][96][98]
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.[94]Tixagevimab/cilgavimab
Regdanvimab
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19.[104] The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.[105][106] The medicine is given by infusion (drip) into a vein.[104][107]
The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.[104]
Regdanvimab was approved for medical use in the European Union in November 2021.[104]